AVEO Pharmaceuticals, Inc. (AVEO) Rating Reiterated by FBR & Co

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “outperform” rating reissued by equities research analysts at FBR & Co in a research report issued to clients and investors on Thursday, July 13th. They presently have a $3.00 price target on the biopharmaceutical company’s stock. FBR & Co’s price target would suggest a potential upside of 9.09% from the company’s current price.

AVEO has been the subject of several other research reports. ValuEngine upgraded AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, June 24th. Piper Jaffray Companies set a $2.00 price target on AVEO Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Finally, Zacks Investment Research raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd.

Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 2.75 on Thursday. AVEO Pharmaceuticals has a one year low of $0.50 and a one year high of $3.19. The firm’s market capitalization is $303.50 million. The company’s 50 day moving average price is $2.20 and its 200 day moving average price is $1.07.

COPYRIGHT VIOLATION NOTICE: This story was originally published by BBNS and is owned by of BBNS. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://baseballnewssource.com/markets/aveo-pharmaceuticals-aveo-outperform-rating-reaffirmed-at-fbr-co-updated-updated-updated/1198512.html.

A number of large investors have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC acquired a new stake in AVEO Pharmaceuticals during the second quarter worth $289,000. Paloma Partners Management Co bought a new position in AVEO Pharmaceuticals during the first quarter valued at about $184,000. UBS Oconnor LLC bought a new position in AVEO Pharmaceuticals during the first quarter valued at about $291,000. Sabby Management LLC bought a new position in AVEO Pharmaceuticals during the first quarter valued at about $513,000. Finally, Renaissance Technologies LLC raised its position in AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 148,500 shares in the last quarter. 51.04% of the stock is owned by hedge funds and other institutional investors.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.